The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

A Multi-center Open-label Trial Evaluating the Efficacy and Safety of Daratumumab SC in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID)

Treatment Trials

Focus your search

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

Description

Conditions